Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
about
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsPTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRMolecular imaging of phosphorylation events for drug developmentPhase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib.IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma.The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications.Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt.Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer.PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapyA phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumorsMEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft modelGanoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer ProgressionAcquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteinsRole of mTOR in anticancer drug resistance: perspectives for improved drug treatment.Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patientsMolecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activityRadiation-induced EGFR-signaling and control of DNA-damage repair.Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group StudyHeterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.Challenges of drug resistance in the management of pancreatic cancer.Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.Targeted therapy in nonmelanoma skin cancers.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer.Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.miRNAs: mediators of ErbB family targeted therapy resistance.Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis.Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
P2860
Q21184033-29487E86-EF2E-429F-AF4F-2E5EFE1A20B4Q27851633-F8702734-A9AD-466E-86C9-BC9AF5B9F069Q28240702-9D9C86CF-7C16-4FB4-996C-C112D0A20FC4Q33388737-BF56C70E-B61F-4CA0-9C22-B7C8ADCDBEB8Q33396953-1E29B805-DC7F-4D9E-8402-C6A4D903AC9EQ33684793-E11A83C8-74D7-4E86-8549-2AD7CCCB620DQ34154783-FC108931-F987-45BB-B274-693F61448084Q34334470-F0C5A557-1DE3-42B6-B99D-CD0DFEBFC2ECQ34442002-1ED8915C-363C-49A2-A0D0-06D773932F22Q34918878-6637FF7F-80E7-43F2-87CC-9DAFD8CC35AAQ34987170-722B8BD0-6CCF-4293-BDC8-AB61EF7E8751Q35167467-3B1DD21A-62F4-44B9-8015-F2F0C03A41BBQ35176147-FEFEDD87-C1D1-4501-B636-182A5B345913Q35653997-BD47EF34-CBBA-40A8-9ABD-64EE5871D7BEQ35854826-46F54CCA-F8EC-47B2-9B02-627DB1A19639Q35872321-B86EDA0A-3B3F-4697-8E92-1B16684C17BBQ36657315-29727C3A-8381-4A53-B343-6237E8448564Q36726112-C293EE4E-A691-4505-AA7C-09F0F1C9FF2BQ36844334-55DE266D-640E-432A-BD49-28AB7EA3570BQ36921093-9AC3298A-B988-4D43-B0D5-C9BBCBA28E86Q36929734-D1505958-5473-4205-B376-4DA6460AE4FDQ36983803-243713BF-9031-41CE-9CD6-4CC664396788Q37015793-510F4E2D-5A29-425B-A301-4AAAE4CAE76BQ37024025-E7C28130-E317-4EBB-B90E-8C84F96C8890Q37249366-C18350A7-738D-43E4-B085-B1B658995E08Q37294922-9B937338-F1F3-47DA-AF1A-C05DFBC329CFQ37628728-B55B0B9F-6405-4F33-9F3A-557B3A803417Q37799830-48F6292C-BF76-459C-BEF5-8FFA196095B9Q38010747-3FD60393-C4C8-4684-918F-8159834EF36AQ38023942-485FC5D9-795A-4978-894C-1E8209CD20F0Q38161358-4E5DA2E5-F28B-4E25-8DBB-6B50112F2016Q38390205-BCA23530-8013-4816-A987-400E84A7E5F6Q38763609-684DBA13-1530-4DE0-9802-42BBAF2A68CDQ38868047-959B3A51-9A3D-4A01-BA67-706B3B82697EQ38881549-1B3298CC-81EB-4BBE-8AB5-309B9B626322Q38893248-907BFE07-534A-45BE-A6CB-859739850BA5Q39022069-6B1F463F-D9B1-4F9A-87B0-FB454B55C7FAQ39101764-9671EE25-FBDC-4126-B9BE-40B2124C15A8Q39365739-1E6922A6-3E63-4EA2-9753-CCFBF2A49246Q39798868-4EBC7606-6789-4A88-B044-884C744C8F12
P2860
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Acquired resistance to erlotin ...... ulation of phosphorylated Akt.
@en
type
label
Acquired resistance to erlotin ...... ulation of phosphorylated Akt.
@en
prefLabel
Acquired resistance to erlotin ...... ulation of phosphorylated Akt.
@en
P2093
P1433
P1476
Acquired resistance to erlotin ...... ulation of phosphorylated Akt.
@en
P2093
Chandra Bartholomeusz
Dongwei Zhang
Edward Felix
Fumiyuki Yamasaki
Gabriel N Hortobagyi
Gordon B Mills
Kaoru Kurisu
Mary J Johansen
Naoto T Ueno
Richard J Aguilar
P304
P356
10.1158/0008-5472.CAN-06-3020
P407
P577
2007-06-01T00:00:00Z